Acute cardiac care & resuscitation
Do DanGer-SHOCK-like patients benefit from veno-arterial ECMO (VA-ECMO) treatment in infarct-related cardiogenic shock? results of an individual patient data meta-analysis
Pooled result · 180-day all-cause mortalityResult — go to the resultHazard ratio 0.84 95% CI 0.56–1.26Authors' conclusion
In this exploratory subgroup analysis in patients with CS, STEMI, and a low likelihood of brain injury, there was no mortality benefit with the routine use of VA-ECMO.
Study context
- Population
- DanGer-Shock-like patients with AMI-related cardiogenic shock (STEMI only, presumed low likelihood of brain injury)
- Participants
- 202 patients4 RCTs
- Comparison
- VA-ECMO vs control
- VA-ECMOn = 106
- Controln = 96reference
- Outcome
- All-cause mortality
- Follow-up
- 180 days
Methodological detailssubgroup analysis, exploratory subgroup analysis, 4 RCTs
- Subgroup analysis
- Exploratory subgroup analysis
- 4 RCTs
Pooled result
180-day all-cause mortality · 6 months
Hazard ratio
0.84
95% CI 0.56–1.26
By group
VA-ECMOvs Control
HR 0.84 (95% CI 0.56–1.26)
As reported in the abstract
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Major bleeding | 2.24 (1.08–4.64) | |
| Peripheral vascular complications | 3.65 (1.15–11.56) | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Do DanGer-SHOCK-like patients benefit from VA-ECMO treatment in infarct-related cardiogenic shock? results of an individual patient data meta-analysis. Eur Heart J Acute Cardiovasc Care. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →